Genetics of anxiety disorders - status quo and quo Vadis

Current Pharmaceutical Design

Volumn 18, Issue 35, 2012, Pages 5691-5698

  Domschke, Katharina ^a   Deckert, Jürgen ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Association; Epigenetics; Gene environment interaction; Genome wide association; Imaging genetics; Linkage; Pharmacogenetics

Indexed keywords

CANNABINOID 1 RECEPTOR; CATECHOL METHYLTRANSFERASE; MONOAMINE OXIDASE A INHIBITOR; NEUROPEPTIDE S; NEUROPEPTIDE Y RECEPTOR; SEROTONIN 1A AGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

AGORAPHOBIA; ANXIETY DISORDER; BLOOD INJECTION PHOBIA; EPIGENETICS; GENERALIZED ANXIETY DISORDER; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; MOLECULAR GENETICS; NEUROPHYSIOLOGY; PANIC; PHARMACOGENETICS; PHENOTYPE; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL PHOBIA;

ANIMALS; ANXIETY DISORDERS; EPIGENESIS, GENETIC; GENE-ENVIRONMENT INTERACTION; GENETIC LINKAGE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIFE CHANGE EVENTS; RISK FACTORS; STARTLE REACTION;

EID: 84869096779     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803530781     Document Type: Review

References (143)

1. Maier W, Lichtermann D, Minges J, Oehrlein A, Franke P. A controlled family study in panic disorder. J Psychiatr Res 1993; 27 Suppl 1:79-87.: 79-87.
2. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001; 158: 1568-78.
3. Yehuda R, Bell A, Bierer LM, Schmeidler J. Maternal, not paternal, PTSD is related to increased risk for PTSD in offspring of Holocaust survivors. J Psychiatr Res 2008; 42: 1104-11.
4. Segman RH, Shalev AY. Genetics of posttraumatic stress disorder. CNS Spectr 2003; 8: 693-8.
5. Stein MB, Jang KL, Taylor S, Vernon PA, Livesley WJ. Genetic and environmental influences on trauma exposure and posttraumatic stress disorder symptoms: a twin study. Am J Psychiatry 2002; 159: 1675-81.
6. True WR, Rice J, Eisen SA, et al. A twin study of genetic and environmental contributions to liability for posttraumatic stress symptoms. Arch Gen Psychiatry 1993; 50: 257-64.
7. Vieland VJ, Goodman DW, Chapman T, Fyer AJ. New segregation analysis of panic disorder. Am J Med Genet 1996; 67: 147-53.
8. Crowe RR, Noyes R, Jr., Wilson AF, Elston RC, Ward LJ. A linkage study of panic disorder. Arch Gen Psychiatry 1987; 44: 933-7.
9. Crowe RR, Goedken R, Samuelson S, et al. Genomewide survey of panic disorder. Am J Med Genet 2001; 105: 105-9.
10. Knowles JA, Fyer AJ, Vieland VJ, et al. Results of a genome-wide genetic screen for panic disorder. Am J Med Genet 1998; 81: 139-47.
11. Gelernter J, Bonvicini K, Page G, et al. Linkage genome scan for loci predisposing to panic disorder or agoraphobia. Am J Med Genet 2001; 105: 548-57.
12. Hamilton SP, Fyer AJ, Durner M, et al. Further genetic evidence for a panic disorder syndrome mapping to chromosome 13q. Proc Natl Acad Sci USA 2003; 100: 2550-5.
13. Thorgeirsson TE, Oskarsson H, Desnica N, et al. Anxiety with panic disorder linked to chromosome 9q in Iceland. Am J Hum Genet 2003; 72: 1221-30.
14. Fyer AJ, Hamilton SP, Durner M, et al. A third-pass genome scan in panic disorder: evidence for multiple susceptibility loci. Biol Psychiatry 2006; 60: 388-401.
15. Kaabi B, Gelernter J, Woods SW, et al. Genome scan for loci predisposing to anxiety disorders using a novel multivariate approach: strong evidence for a chromosome 4 risk locus. Am J Hum Genet 2006; 78: 543-53.
16. MacKinnon DF, Xu J, McMahon FJ, et al. Bipolar disorder and panic disorder in families: an analysis of chromosome 18 data. Am J Psychiatry 1998; 155: 829-31.
17. Logue MW, Durner M, Heiman GA, et al. A linkage search for joint panic disorder/bipolar genes. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 1139-46.
18. Weissman MM, Fyer AJ, Haghighi F, et al. Potential panic disorder syndrome: clinical and genetic linkage evidence. Am J Med Genet 2000; 96: 24-35.
19. Gelernter J, Page GP, Bonvicini K, et al. A chromosome 14 risk locus for simple phobia: results from a genomewide linkage scan. Mol Psychiatry 2003; 8: 71-82.
20. Gelernter J, Page GP, Stein MB, Woods SW. Genome-wide linkage scan for loci predisposing to social phobia: evidence for a chromosome 16 risk locus. Am J Psychiatry 2004; 161: 59-66.
21. Smoller JW, Gardner-Schuster E, Covino J. The genetic basis of panic and phobic anxiety disorders. Am J Med Genet C Semin Med Genet 2008; 148C: 118-26.
22. Deckert J, Nothen MM, Franke P, et al. Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease. Mol Psychiatry 1998; 3: 81-5.
23. Hamilton SP, Slager SL, De Leon AB, et al. Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology 2004; 29: 558-65.
24. Kennedy JL, Bradwejn J, Koszycki D, et al. Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry 1999; 4: 284-5.
25. Hosing VG, Schirmacher A, Kuhlenbaumer G, et al. Cholecystokinin- and cholecystokinin-B-receptor gene polymorphisms in panic disorder. J Neural Transm Suppl 2004; 147-56.
26. Deckert J, Catalano M, Syagailo YV, et al. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet 1999; 8: 621-4.
27. Samochowiec J, Hajduk A, Samochowiec A, et al. Association studies of MAO-A, COMT, and 5-HTT genes polymorphisms in patients with anxiety disorders of the phobic spectrum. Psychiatry Res 2004; 128: 21-6.
28. Hamilton SP, Slager SL, Heiman GA, et al. Evidence for a susceptibility locus for panic disorder near the catechol-Omethyltransferase gene on chromosome 22. Biol Psychiatry 2002; 51: 591-601.
29. Domschke K, Freitag CM, Kuhlenbaumer G, et al. Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women. Int J Neuropsychopharmacol 2004; 7: 183-8.
30. Domschke K, Deckert J, O'donovan MC, Glatt SJ. Meta-analysis of COMT val158met in panic disorder: ethnic heterogeneity and gender specificity. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 667-73.
31. Rothe C, Gutknecht L, Freitag C, et al. Association of a functional 1019C>G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia. Int J Neuropsychopharmacol 2004; 7: 189-92.
32. Huang YY, Battistuzzi C, Oquendo MA, et al. Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. Int J Neuropsychopharmacol 2004; 7: 441-51.
33. Blaya C, Salum GA, Moorjani P, et al. Panic disorder and serotonergic genes (SLC6A4, HTR1A and HTR2A): Association and interaction with childhood trauma and parenting. Neurosci Lett 2010; 485: 11-5.
34. Leygraf A, Hohoff C, Freitag C, et al. Rgs 2 gene polymorphisms as modulators of anxiety in humans? J Neural Transm 2006; 113: 1921-5.
35. Smoller JW, Paulus MP, Fagerness JA, et al. Influence of RGS2 on anxiety-related temperament, personality, and brain function. Arch Gen Psychiatry 2008; 65: 298-308.
36. Rowe DC, Stever C, Gard JM, et al. The relation of the dopamine transporter gene (DAT1) to symptoms of internalizing disorders in children. Behav Genet 1998; 28: 215-25.
37. McGrath M, Kawachi I, Ascherio A, et al. Association between catechol-O-methyltransferase and phobic anxiety. Am J Psychiatry 2004; 161: 1703-5.
38. Lochner C, Hemmings S, Seedat S, et al. Genetics and personality traits in patients with social anxiety disorder: a case-control study in South Africa. Eur Neuropsychopharmacol 2007; 17: 321-7.
39. Tadic A, Rujescu D, Szegedi A, et al. Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. Am J Med Genet B Neuropsychiatr Genet 2003; 117B: 1-6.
40. Lee HJ, Lee MS, Kang RH, et al. Influence of the serotonin transporter promoter gene polymorphism on susceptibility to posttraumatic stress disorder. Depress Anxiety 2005; 21: 135-9.
41. Cornelis MC, Nugent NR, Amstadter AB, Koenen KC. Genetics of post-traumatic stress disorder: review and recommendations for genome-wide association studies. Curr Psychiatry Rep 2010; 12: 313-26.
42. Koenen KC. Genetics of posttraumatic stress disorder: Review and recommendations for future studies. J Trauma Stress 2007; 20: 737-50.
43. Pervanidou P. Biology of post-traumatic stress disorder in childhood and adolescence. J Neuroendocrinol 2008; 20: 632-8.
44. Unschuld PG, Ising M, Erhardt A, et al. Polymorphisms in the galanin gene are associated with symptom-severity in female patients suffering from panic disorder. J Affect Disord 2008; 105: 177-84.
45. Domschke K, Hohoff C, Jacob C, et al. Chromosome 4q31-34 panic disorder risk locus: association of neuropeptide Y Y5 receptor variants. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 510-6.
46. Domschke K, Reif A, Weber H, et al. Neuropeptide S receptor gene converging evidence for a role in panic disorder. Mol Psychiatry 2011; 16: 938-48.
47. Donner J, Haapakoski R, Ezer S, et al. Assessment of the neuropeptide S system in anxiety disorders. Biol Psychiatry 2010; 68: 474-83.
48. Okamura N, Hashimoto K, Iyo M, et al. Gender-specific association of a functional coding polymorphism in the Neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1444-8.
49. Koenen KC, Amstadter AB, Ruggiero KJ, et al. RGS2 and generalized anxiety disorder in an epidemiologic sample of hurricane-exposed adults. Depress Anxiety 2009; 26: 309-15.
50. Lu AT, Ogdie MN, Jarvelin MR, et al. Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1488-94.
51. Hamilton SP. Linkage and association studies of anxiety disorders. Depress Anxiety 2009; 26: 976-83.
52. Maron E, Hettema JM, Shlik J. Advances in molecular genetics of panic disorder. Mol Psychiatry 2010; 15: 681-701.
53. Otowa T, Yoshida E, Sugaya N, et al. Genome-wide association study of panic disorder in the Japanese population. J Hum Genet 2009; 54: 122-6.
54. Otowa T, Tanii H, Sugaya N, et al. Replication of a genome-wide association study of panic disorder in a Japanese population. J Hum Genet 2010; 55: 91-6.
55. Erhardt A, Czibere L, Roeske D, et al. TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry 2011; 16: 647-63.
56. Gregersen N, Dahl HA, Buttenschon HN, et al. A genome-wide study of panic disorder suggests the amiloride-sensitive cation channel 1 as a candidate gene. Eur J Hum Genet 2012; 20: 84-90.
57. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-45.
58. Hariri AR, Mattay VS, Tessitore A, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002; 297: 400-3.
59. Grillon C, Baas J. A review of the modulation of the startle reflex by affective states and its application in psychiatry. Clin Neurophysiol 2003; 114: 1557-79.
60. Domschke K, Ohrmann P, Braun M, et al. Influence of the catechol-O-methyltransferase val158met genotype on amygdala and prefrontal cortex emotional processing in panic disorder. Psychiatry Res 2008; 163: 13-20.
61. Domschke K, Braun M, Ohrmann P, et al. Association of the functional -1019C/G 5-HT1A polymorphism with prefrontal cortex and amygdala activation measured with 3 T fMRI in panic disorder. Int J Neuropsychopharmacol 2006; 9: 349-55.
62. Furmark T, Appel L, Henningsson S, et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci 2008; 28: 13066-74.
63. Furmark T, Henningsson S, Appel L, et al. Genotype overdiagnosis in amygdala responsiveness: affective processing in social anxiety disorder. J Psychiatry Neurosci 2009; 34: 30-40.
64. Furmark T, Tillfors M, Garpenstrand H, et al. Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci Lett 2004; 362: 189-92.
65. Lau JY, Goldman D, Buzas B, et al. BDNF gene polymorphism (Val66Met) predicts amygdala and anterior hippocampus responses to emotional faces in anxious and depressed adolescents. Neuroimage 2010; 53: 952-61.
66. Lau JY, Goldman D, Buzas B, et al. Amygdala function and 5- HTT gene variants in adolescent anxiety and major depressive disorder. Biol Psychiatry 2009; 65: 349-55.
67. Domschke K, Dannlowski U. Imaging genetics of anxiety disorders. Neuroimage 2010; 53: 822-31.
68. Domschke K, Stevens S, Beck B, et al. Blushing propensity in social anxiety disorder: influence of serotonin transporter gene variation. J Neural Transm 2009; 116: 663-6.
69. Hohoff C, Domschke K, Schwarte K, et al. Sympathetic activity relates to adenosine A(2A) receptor gene variation in blood-injury phobia. J Neural Transm 2009; 116: 659-62.
70. Montag C, Buckholtz JW, Hartmann P, et al. COMT genetic variation affects fear processing: psychophysiological evidence. Behav Neurosci 2008; 122: 901-9.
71. Lonsdorf TB, Ruck C, Bergstrom J, et al. The symptomatic profile of panic disorder is shaped by the 5-HTTLPR polymorphism. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1479-83.
72. Klumpers F, Heitland I, Oosting RS, Kenemans JL, Baas JM. Genetic variation in serotonin transporter function affects human fear expression indexed by fear-potentiated startle. Biol Psychol 2012; 89: 277-82.
73. Alsene K, Deckert J, Sand P, de WH. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 2003; 28: 1694-702.
74. Childs E, Hohoff C, Deckert J, et al. Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 2008; 33: 2791-800.
75. Rogers PJ, Hohoff C, Heatherley SV, et al. Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption. Neuropsychopharmacology 2010; 35: 1973-83.
76. Domschke K, Gajewska A, Winter B, et al. ADORA2A Gene Variation, Caffeine, and Emotional Processing: A Multi-level Interaction on Startle Reflex. Neuropsychopharmacology 2012; 37: 759-69.
77. Stein MB, Walker JR, Anderson G, et al. Childhood physical and sexual abuse in patients with anxiety disorders and in a community sample. Am J Psychiatry 1996; 153: 275-7.
78. Bandelow B, Spath C, Tichauer GA, et al. Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with panic disorder. Compr Psychiatry 2002; 43: 269-78.
79. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. Childhood parental loss and adult psychopathology in women. A twin study perspective. Arch Gen Psychiatry 1992; 49: 109-16.
80. Bandelow B, Alvarez TG, Spath C, et al. Separation anxiety and actual separation experiences during childhood in patients with panic disorder. Can J Psychiatry 2001; 46: 948-52.
81. Faravelli C. Life events preceding the onset of panic disorder. J Affect Disord 1985; 9: 103-5.
82. Klauke B, Deckert J, Reif A, Pauli P, Domschke K. Life events in panic disorder-an update on candidate stressors. Depress Anxiety 2010; 27: 716-30.
83. Watt MC, Stewart SH. Anxiety sensitivity mediates the relationships between childhood learning experiences and elevated hypochondriacal concerns in young adulthood. J Psychosom Res 2000; 49: 107-18.
84. Scher CD, Stein MB. Developmental antecedents of anxiety sensitivity. J Anxiety Disord 2003; 17: 253-69.
85. Grabe HJ, Spitzer C, Schwahn C, et al. Serotonin transporter gene (SLC6A4) promoter polymorphisms and the susceptibility to posttraumatic stress disorder in the general population. Am J Psychiatry 2009; 166: 926-33.
86. Kilpatrick DG, Koenen KC, Ruggiero KJ, et al. The serotonin transporter genotype and social support and moderation of posttraumatic stress disorder and depression in hurricane-exposed adults. Am J Psychiatry 2007; 164: 1693-9.
87. Koenen KC, Aiello AE, Bakshis E, et al. Modification of the association between serotonin transporter genotype and risk of posttraumatic stress disorder in adults by county-level social environment. Am J Epidemiol 2009; 169: 704-11.
88. Kolassa IT, Ertl V, Eckart C, et al. Association study of trauma load and SLC6A4 promoter polymorphism in posttraumatic stress disorder: evidence from survivors of the Rwandan genocide. J Clin Psychiatry 2010; 71: 543-7.
89. Binder EB, Bradley RG, Liu W, et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 2008; 299: 1291-305.
90. Xie P, Kranzler HR, Poling J, et al. Interaction of FKBP5 with childhood adversity on risk for post-traumatic stress disorder. Neuropsychopharmacology 2010; 35: 1684-92.
91. Mustapic M, Pivac N, Kozaric-Kovacic D, et al. Dopamine betahydroxylase (DBH) activity and -1021C/T polymorphism of DBH gene in combat-related post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 1087-9.
92. Amstadter AB, Koenen KC, Ruggiero KJ, et al. Variant in RGS2 moderates posttraumatic stress symptoms following potentially traumatic event exposure. J Anxiety Disord 2009; 23: 369-73.
93. Nelson EC, Agrawal A, Pergadia ML, et al. Association of childhood trauma exposure and GABRA2 polymorphisms with risk of posttraumatic stress disorder in adults. Mol Psychiatry 2009; 14: 234-5.
94. Kolassa IT, Kolassa S, Ertl V, Papassotiropoulos A, de Quervain DJ. The risk of posttraumatic stress disorder after trauma depends on traumatic load and the catechol-o-methyltransferase Val(158)Met polymorphism. Biol Psychiatry 2010; 67: 304-8.
95. Nugent NR, Tyrka AR, Carpenter LL, Price LH. Gene-environment interactions: early life stress and risk for depressive and anxiety disorders. Psychopharmacology (Berl) 2011; 214: 175-96.
96. Laucht M, Treutlein J, Blomeyer D, et al. Interaction between the 5-HTTLPR serotonin transporter polymorphism and environmental adversity for mood and anxiety psychopathology: evidence from a high-risk community sample of young adults. International Journal of Neuropsychopharmacology 2009; 12: 737-47.
97. Klauke B, Deckert J, Reif A, et al. Serotonin transporter gene and childhood trauma--a G x E effect on anxiety sensitivity. Depress Anxiety 2011; 28: 1048-57.
98. Stein MB, Schork NJ, Gelernter J. Gene-by-environment (serotonin transporter and childhood maltreatment) interaction for anxiety sensitivity, an intermediate phenotype for anxiety disorders. Neuropsychopharmacology 2008; 33: 312-9.
99. Witt SH, Buchmann AF, Blomeyer D, et al. An interaction between a neuropeptide Y gene polymorphism and early adversity modulates endocrine stress responses. Psychoneuroendocrinology 2011.
100. Klauke B, Deckert J, Zwanzger P, et al. Neuropeptide S receptor gene (NPSR) and life events: GxE effects on anxiety sensitivity and its subdimensions. World J Biol Psychiatry 2012; in press.
101. Amstadter AB, Koenen KC, Ruggiero KJ, et al. NPY moderates the relation between hurricane exposure and generalized anxiety disorder in an epidemiologic sample of hurricane-exposed adults. Depression and Anxiety 2010; 27: 270-5.
102. Poulton R, Andrews G, Millichamp J. Gene-environment interaction and the anxiety disorders. Eur Arch Psychiatry Clin Neurosci 2008; 258: 65-8.
103. Thomas D. Gene-environment-wide association studies: emerging approaches. Nat Rev Genet 2010; 11: 259-72.
104. Muinos-Gimeno M, Espinosa-Parrilla Y, Guidi M, et al. Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 are associated with panic disorder and regulate several anxiety candidate genes and related pathways. Biol Psychiatry 2011; 69: 526-33.
105. Saus E, Brunet A, Armengol L, et al. Comprehensive copy number variant (CNV) analysis of neuronal pathways genes in psychiatric disorders identifies rare variants within patients. J Psychiatr Res 2010; 44: 971-8.
106. Kawamura Y, Otowa T, Koike A, et al. A genome-wide CNV association study on panic disorder in a Japanese population. J Hum Genet 2011; 56: 852-6.
107. Jia P, Wang L, Meltzer HY, Zhao Z. Pathway-based analysis of GWAS datasets: effective but caution required. Int J Neuropsychopharmacol 2011; 14: 567-72.
108. O'Dushlaine C, Kenny E, Heron E, et al. Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility. Mol Psychiatry 2011; 16: 286-92.
109. Gormanns P, Mueller NS, Ditzen C, et al. Phenome-transcriptome correlation unravels anxiety and depression related pathways. J Psychiatr Res 2011; 45: 973-9.
110. Lyon GJ, Jiang T, Van WR, et al. Exome sequencing and unrelated findings in the context of complex disease research: ethical and clinical implications. Discov Med 2011; 12: 41-55.
111. Xu B, Roos JL, Dexheimer P, et al. Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat Genet 2011; 43: 864-8.
112. Gratacos M, Costas J, de CR, et al. Identification of new putative susceptibility genes for several psychiatric disorders by association analysis of regulatory and non-synonymous SNPs of 306 genes involved in neurotransmission and neurodevelopment. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 808-16.
113. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33: 245-54.
114. Chertkow-Deutsher Y, Cohen H, Klein E, Ben-Shachar D. DNA methylation in vulnerability to post-traumatic stress in rats: evidence for the role of the post-synaptic density protein Dlgap2. Int J Neuropsychopharmacol 2010; 13: 347-59.
115. Lesch KP. When the serotonin transporter gene meets adversity: the contribution of animal models to understanding epigenetic mechanisms in affective disorders and resilience. Curr Top Behav Neurosci 2011; 7:251-80.: 251-80.
116. Roth TL, Sweatt JD. Epigenetic marking of the BDNF gene by early-life adverse experiences. Horm Behav 2011; 59: 315-20.
117. Kinnally EL, Feinberg C, Kim D, et al. DNA methylation as a risk factor in the effects of early life stress. Brain Behav Immun 2011; 25: 1548-53.
118. Diemer J, Vennewald N, Domschke K, Zwanzger P. Therapyrefractory panic: current research areas as possible perspectives in the treatment of anxiety. Eur Arch Psychiatry Clin Neurosci 2010; 260 Suppl 2:S127-31. Epub;%2010 Oct 9.: S127-S131.
119. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005; 102: 10604-9.
120. Smith AK, Conneely KN, Kilaru V, et al. Differential immune system DNA methylation and cytokine regulation in post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 700-8.
121. Uddin M, Aiello AE, Wildman DE, et al. Epigenetic and immune function profiles associated with posttraumatic stress disorder. Proc Natl Acad Sci USA 2010; 107: 9470-5.
122. Uddin M, Galea S, Chang SC, et al. Gene expression and methylation signatures of MAN2C1 are associated with PTSD. Dis Markers 2011; 30: 111-21.
123. Koenen KC, Uddin M, Chang SC, et al. SLC6A4 methylation modifies the effect of the number of traumatic events on risk for posttraumatic stress disorder. Depress Anxiety 2011; 28: 639-47.
124. Domschke K, Tidow N, Kuithan H, et al. Monoamine oxidase A gene DNA hypomethylation a risk factor for panic disorder? Int J. Neuropsychopharmacol 2012, in press.
125. Ursini G, Bollati V, Fazio L, et al. Stress-related methylation of the catechol-O-methyltransferase Val 158 allele predicts human prefrontal cognition and activity. J Neurosci 2011; 31: 6692-8.
126. Slaap BR, den Boer JA. The prediction of nonresponse to pharmacotherapy in panic disorder: a review. Depress Anxiety 2001; 14: 112-22.
127. Franchini L, Serretti A, Gasperini M, Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998; 32: 255-9.
128. O'Reilly RL, Bogue L, Singh SM. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry 1994; 36: 467-71.
129. Porcelli S, Drago A, Fabbri C, et al. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 2011; 36: 87-113.
130. Perna G, Favaron E, Di BD, Bussi R, Bellodi L. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology 2005; 30: 2230-5.
131. Stein MB, Seedat S, Gelernter J. Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl) 2006; 187: 68-72.
132. Saeki Y, Watanabe T, Ueda M, et al. Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder. Eur J Clin Pharmacol 2009; 65: 685-91.
133. Ishiguro S, Watanabe T, Ueda M, et al. Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. Eur J Clin Pharmacol 2011; 67: 1213-21.
134. Yevtushenko OO, Oros MM, Reynolds GP. Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. J Affect Disord 2010; 123: 308-11.
135. Lohoff FW, Aquino TD, Narasimhan S, et al. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J 2011; in press.
136. Lenze EJ, Goate AM, Nowotny P, et al. Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults. J Clin Psychopharmacol 2010; 30: 672-7.
137. Narasimhan S, Aquino TD, Hodge R, Rickels K, Lohoff FW. Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Neurosci Lett 2011; 503: 200-2.
138. Lonsdorf TB, Ruck C, Bergstrom J, et al. The OMTval158met polymorphism is associated with symptom relief during exposurebased cognitive-behavioral treatment in panic disorder. BMC Psychiatry 2010; 10: 99.
139. Domschke K, Zwanzger P. GABAergic and endocannabinoid dysfunction in anxiety future therapeutic targets? Curr Pharm Des 2008; 14: 3508-17.
140. Lukas M, Neumann ID. Nasal application of neuropeptide S reduces anxiety and prolongs memory in rats: social versus nonsocial effects. Neuropharmacology 2012; 62: 398-405.
141. Hamm CA, Costa FF. The impact of epigenomics on future drug design and new therapies. Drug Discov Today 2011; 16: 626-35.
142. Deckert J, Arolt V. Genetische Forschung in der Psychiatrie: Fortschritt und Ethische Verantwortung. In: Raem A, Braun R, Fenger H, Michaelis W, Nikol S, Winter S, Eds. Genmedizin. Berlin: Springer; 2000. pp. 477-91.
143. Serretti A, Artioli P. Ethical problems in pharmacogenetic studies of psychiatric disorders. Pharmacogenomics J 2006; 6: 289-95.